Product Images Lisdexamfetamine Dimesylate
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 10 images provide visual information about the product associated with Lisdexamfetamine Dimesylate NDC 72162-2452 by Bryant Ranch Prepack, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
Label - lbl721622452
The text contains information about Lisdexamfetamine capsules containing 20 mg of lisdexamfetamine dimesylate per capsule. It instructs to dispense the medication guide to each patient and store the capsules within certain temperature excursions. The manufacturer is mentioned as Bryant Ranch Prepack, Inc, and the medication is to be kept out of reach of children.*
Chemical Structure - lisdexcaps 01
Figure 1 - lisdexcaps 02
Special Population - This text discusses the consideration of specific populations in research or clinical settings. It mentions the evaluation of gender (Male/Female) and age groups ranging from 65 to greater than 75 years. It also includes categories for different levels of renal impairment: Mild, Moderate, Severe, and End-Stage Renal Disease. Additionally, it mentions a "Fold Change and 90% CI" related to a reference point, suggesting a statistical analysis or comparison being conducted.*
Figure 2 - lisdexcaps 03
This appears to be a list of medications or substances with their corresponding changes in Cmax and AUC values. The text also mentions fold change and a reference point. It seems to be a report or data comparison regarding the impact of these substances on certain parameters.*
Figure 3 - lisdexcaps 04
This is not-available.*
Figure 4 - lisdexcaps 05
Figure 5 - lisdexcaps 06
Figure 6 - lisdexcaps 07
This is a description of LS Mean (SE) PERMP Total Scores at different time points post-dose for both Phacebo and Lisdexamfetamine. The data presents the scores for each medication at 4, 8, 12, and 14 hours post-dose.*
Figure 7 - lisdexcaps 08
This is a chart showing the proportion of subjects experiencing relapse or treatment failure over time (in days) in a study involving Lisdexamfetamine. The data is represented as a percentage.*
Figure 8 - lisdexcaps 09
Not available.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
